drugset / Trial / NCT06727396
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.
Timeline
- Start
- 2024-11-14
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-508 | Unknown | — | — |
Indications
No indication recorded.